… Experience from ex vivo and in vivo animal experiments, p. 83. In: New developments in con…
KSENDAL AN & JYNGE P.: Myocardial protection by micromolar manganese in the calcium …

… Per Jynge is a co-founder of PledPharma and owns shares in this company. PJ is inventor
on several granted patent families covering the therapeutic use of PLED derivatives. Torsten …

Previous methods for high performance liquid chromatography (HPLC) measurements of
myocardial high energy phosphate (HEP) compounds have used either two different assays or …

Myocardial preservation by continuous coronary perfusion is compared with cold cardioplegia.
The I L. of St. Thomas’ cardioplegic protective solution used for infusion into the coronary …

… Data are expressed as mean with p values (two-tailed) included. Data in three rows to the
right were obtained by the use of late Gd-enhancement MRI (gadopentetate dimeglumine). …

Following detailed investigation and definition of some of the critical factors relating to the
composition and use of cardioplegic protective solutions, we have formulated the St. Thomas' …

Manganese dipyridoxyl diphosphate (MnDPDP) is a contrast agent for magnetic resonance
imaging (MRI) of the liver. Aims of the study were to examine if MnDPDP possesses …

… The number above the upper whiskers illustrates the p-value between 8-iso-PGF2a at the
actual time points compared to before reperfusion (t0) estimated by Wilcoxon signed ranks test…

… Mean precontrast R 1 was 0.87 ± 0.06 second –1 in infarcted regions and 0.96 ± 0.03 second
–1 in remote regions (P < 0.001). Mean R 1 change over one hour was 0.24 ± 0.07 second …

A number of cardioplegic and protective solutions have been described for the reduction of
cellular damage during ischemic cardiac arrest. These solutions are designed to induce …